drugset / Trial / NCT04885634
Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
Phase 3
Withdrawn
Axel Brandes
Esbjerg Hospital - University Hospital of Southern Denmark · collabHerlev and Gentofte Hospital · collabHillerod Hospital, Denmark · collabSvendborg Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this pilot study is to assess the feasibility of a double-blind, randomized placebo-controlled trial of semaglutide 2.4 mg subcutaneously once weekly on top of standard care compared to standard care alone.
Timeline
- Start
- 2022-10
- Primary completion
- 2024-01
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Semaglutide | Peptide | 2.4 mg | Subcutaneous |